
Drug Development Pharma - November 25, 2013
European approval for Lundbeck and Otsuka
Lundbeck and Otsuka Pharmaceutical Co., Ltd. (Otsuka) have announced marketing authorisation approval from the European Commission for Abilify Maintena (aripiprazole). Abilify Maintena is an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole. “Studies have shown that the early use of long-acting injectables can prevent a person with schizophrenia […]

Collaboration - November 4, 2013
Otsuka named as Lundbeck’s partner in Japan on Nalmefene
Danish Lundbeck and Japanese Otsuka Pharmaceutical have announced that the companies’ existing alliance now also includes the development and commercialization of Nalmefene in Japan. Under the terms of the agreement, Lundbeck will receive an initial payment of EUR 50 million from Otsuka upon signing. Lundbeck will finance the development costs and has an option to […]